Table 1 Details of the affected persons... | American Society of Hematology

Table 1

Details of the affected persons (III:6, IV:5, and V:4) and the unaffected carriers (III:2, III:7, III:9, and IV:6) of the CFH/CFHR3 hybrid gene

Patient ID	Age at presentation	Sex	Clinical outcome	Length of follow-up, y	Transplanted	C3, g/L	C4, g/L	Factor H, g/L	Factor I, mg/L
III:6	44 y	Male	ESRF	11	Yes recurrence	0.86	0.36	0.70	63
IV:5	25 y	Female	ESRF	3	No	0.81	0.36	0.59	67
V:4	9 mo	Female	Recovered renal function, PE×1/2 weeks	2	No	0.96	0.15	0.45	49
III:2		Female				1.67	0.31	0.62	78
III:7		Male				1.29	0.22	0.66	79
III:9		Female				1.61	0.31	0.60	81
IV:6		Female				1.76	0.37	0.38	76

Patient ID	Age at presentation	Sex	Clinical outcome	Length of follow-up, y	Transplanted	C3, g/L	C4, g/L	Factor H, g/L	Factor I, mg/L
III:6	44 y	Male	ESRF	11	Yes recurrence	0.86	0.36	0.70	63
IV:5	25 y	Female	ESRF	3	No	0.81	0.36	0.59	67
V:4	9 mo	Female	Recovered renal function, PE×1/2 weeks	2	No	0.96	0.15	0.45	49
III:2		Female				1.67	0.31	0.62	78
III:7		Male				1.29	0.22	0.66	79
III:9		Female				1.61	0.31	0.60	81
IV:6		Female				1.76	0.37	0.38	76

ESRF indicates end-stage renal failure; and PE, plasma exchange.